Clinical trial
A Safety and Efficacy Study of a Single Center, Open-label, Single Arm About the Gene Correction of HBB in Patient-specific iHSCs Using CRISPR/Cas9 That Intervent Subjests With β-thalassemia Mutations
NCT03728322 is registered in ClinicalTrials.gov with Allife Medical Science and Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Safety and Efficacy Study of a Single Center, Open-label, Single Arm About the Gene Correction of HBB in Patient-specific iHSCs Using CRISPR/Cas9 That Intervent Subjests With β-thalassemia Mutations
- Lead sponsor
- Allife Medical Science and Technology Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- January 31, 2019
- Completion date
- January 31, 2021
- Enrollment
- 12 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.